View Older Stories View More Recent Stories
-
Roth Capital Cuts Price Target on Quicksilver (ZQK) Following 2Q15 Results
-
Roth Sees Peregrine Pharma (PPHM) Entering Key Execution Phase; Affirms at 'Buy'
-
Roth Capital Raises Price Target on Radiant Logistics (RLGT) Following Announced Acquisitions
-
RCA HGB-208 Pushback Seen as 'Modest Stumble', Roth Capital Says
-
Roth Capital Remains Bullish on Craft Brewers Alliance (BREW) Following Investor Meetings
-
Notable Analyst Rating Changes 6/9: (ECR) (AMED) (NBL) Upgraded; (CTXS) (ALV) (AKAM) Downgraded
-
Draft Guidance From FDA 'Potentially Supportive' of Sarepta (SRPT) Accelerated Approval, Roth Capital Says
-
Roth Capital Reiterates Bullish View on bluebird bio (BLUE) Ahead of EHA Data
-
Roth Capital Upgrades QLT Inc (QLTI) to Buy
-
Ballard Power (BLDP) $10M China Bus Deal Lays Foundation for Similar Deals, Roth Capital Says
-
InSite Vision to Merge With Canadian Biotechnology Company QLT
-
Roth Capital 'Impressed' with '6972 Safety Profile; Affirms Ligand Pharma (LGND) at 'Buy'
-
Enphase Energy to Participate at Upcoming ROTH Capital Partners Conference
-
Roth Capital Reiterates Buy Ahead of Vical (VICL) HSV-2 Data
-
Cachet Financial Solutions Completes $4.4 Million Private Placement
-
Sarepta Therapeutic (SRPT) Highlighted at Roth Capital as DMD-Sector Heats Up Into Summer
-
Roth Capital Trims PT on Yingli Green Energy (YGE) to $1.30 Following Q1 Report
-
Atossa Genetics (ATOS) Announces $6.22 Common Stock, Warrants Direct Placement
-
Atossa Genetics Inc. to Raise Approximately $6,220,000 From Institutional Healthcare Investors
-
Roth Capital Raised Price Target Following Ligand Pharma (LGND) Receipt of Milestone Payment
-
Roth Capital Downgrades Zumiez, Inc. (ZUMZ) to Neutral
-
Positive FDA Committee Vote on Flibanserin Bodes Well for Palatin's (PTN) Bremelanotide - Roth Capital
-
Roth Capital Starts Mad Catz Interactive (MCZ) at Buy
-
Notable Analyst Rating Changes 6/4: (CAVM) (T) (FTR) Upgraded; (TWTR) (DDS) (VZ) Downgraded
-
Roth Capital Maintains Buy Rating on Pixelworks (PXLW) Following Asus Design Win
-
Roth Capital Starts Coeur d'Alene Mines (CDE) at Buy
-
Sky-mobi Announces Appointment of New Independent Director
-
Detwiler Fenton Group Adds Investment Banking
-
Roth Capital Assumes Dot Hill (HILL) at Buy
-
Celator Pharmaceuticals (CPXX) Phase III Induction CR/CRi Data 'Major Catalyst', Roth Capital Says
-
Notable Mergers and Acquisitions 6/3: (STCK) (URRE) (BABA)
-
Uranium Resources (URRE), Anatolia Energy to Merge
-
Uranium Resources and Anatolia Energy Announce Merger with Aim to Fast-Track Uranium Production
-
Roth Capital Cuts Price Target on ReneSola (SOL) Following Q1 Miss and Weak Guidance
-
Roth Capital Maintains Buy on Power Solutions (PSIX) Following a Revised Outlook
-
ReneSola (SOL) Plans to Wind Down OEM Operations; Roth Affirms at 'Neutral' Following Q1 Results, Outlook
-
Roth Capital Maintains Bullish View on uniQure BV (QURE) Ahead of Data; Sees as Potential Takeout Candidate
-
Roth 'Encouraged' by Progress in Phase II GANNET53; Reaffirms Synta (SNTA) at 'Buy'
-
Notable 52-Week Highs and Lows 6/2: (ETFC) (RXDX) (AER) High; (OGE) (CZR) Low
-
Notable Analyst Rating Changes 6/2: (GFI) (ZION) (BUD) Upgraded; (ALTR) (IRM) (ITC) Downgraded
-
Pre-Open Stock Movers 06/02: (AVEO) (VICL) (TA) Higher; (SOL) (TUBE) (RGLS) Lower (more...)
-
Roth Capital Starts Cogentix Medical (CGNT) at Neutral
-
Roth Capital Remains Bullish on Curis (CRIS) Following '907 Presentation at ASCO
-
Roth Capital Starts Vical (VICL) at Buy; $4.65 PT
-
Roth Capital Starts Evolution Petroleum (EPM) at Buy
-
Roth Affirms Vascular Biogenics (VBLT) at 'Buy' Following VB-111 in rGBM Update; Phase 3 Study is 'Well Designed'
-
Roth Capital Reiterates Buy on Pacific Ethanol (PEIX) Following Proposed Ethanol RVOs
-
CTI BioPharma (CTIB) Pacritinib a Real Threat to Ruxolitinib, Roth Capital Says
-
Roth Capital Bullish on Green Plains (GPRE) Following Proposed Ethanol RVOs
-
Power Solutions International to Present at Upcoming Investor Conferences

